S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Biohaven Pharmaceutical Stock Forecast, Price & News

+0.23 (+0.22%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
342,241 shs
Average Volume
584,269 shs
Market Capitalization
$6.90 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Biohaven Pharmaceutical logo

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.


Biohaven Pharmaceutical (NYSE:BHVN) PT Raised to $144.00 at Mizuho
November 18, 2021 |  americanbankingnews.com
Biohaven Pharma Hldgs Insider Makes $610K Stock Purchase
November 11, 2021 |  finance.yahoo.com
Traders Should Be Stopped Out of Biohaven Pharmaceutical
November 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$63.63 million
Book Value
($9.03) per share


Net Income
$-766.80 million
Net Margins
Pretax Margin




Free Float
Market Cap
$6.90 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.72 out of 5 stars

Medical Sector

49th out of 1,394 stocks

Pharmaceutical Preparations Industry

15th out of 674 stocks

Analyst Opinion: 4.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

Is Biohaven Pharmaceutical a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Biohaven Pharmaceutical stock.
View analyst ratings for Biohaven Pharmaceutical
or view top-rated stocks.

How has Biohaven Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BHVN shares have increased by 167.0% and is now trading at $105.37.
View which stocks have been most impacted by COVID-19

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Biohaven Pharmaceutical

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) posted its earnings results on Monday, November, 8th. The company reported ($2.63) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by $0.23. The firm earned $135.74 million during the quarter, compared to analysts' expectations of $128.40 million. Biohaven Pharmaceutical's revenue for the quarter was up 668.5% compared to the same quarter last year. During the same period last year, the business posted ($3.27) earnings per share.
View Biohaven Pharmaceutical's earnings history

What guidance has Biohaven Pharmaceutical issued on next quarter's earnings?

Biohaven Pharmaceutical issued an update on its third quarter 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $136 million-$136 million, compared to the consensus revenue estimate of $123.69 million.

What price target have analysts set for BHVN?

11 Wall Street analysts have issued 12-month price objectives for Biohaven Pharmaceutical's stock. Their forecasts range from $105.00 to $177.00. On average, they expect Biohaven Pharmaceutical's share price to reach $144.60 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price.
View analysts' price targets for Biohaven Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the following people:
  • Vladimir Coric, Chief Executive Officer & Director
  • Lisa Stocking, Director-Operations & Regulatory Affairs
  • James Engelhart, Chief Financial Officer & Treasurer
  • Charles Conway, Chief Scientific Officer
  • Elyse Stock, Chief Medical Officer

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Capital World Investors (9.26%), BlackRock Inc. (7.04%), Marshall Wace LLP (4.15%), Polar Capital Holdings Plc (1.92%), Bank of New York Mellon Corp (1.91%) and Alliancebernstein L.P. (1.65%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, Robert Berman and William A Jones Jr.
View institutional ownership trends for Biohaven Pharmaceutical

Which institutional investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Glenview Capital Management LLC, Alliancebernstein L.P., Hood River Capital Management LLC, Wellington Management Group LLP, ARS Investment Partners LLC, BlackRock Inc., Lombard Odier Asset Management Switzerland SA, and Rhenman & Partners Asset Management AB.
View insider buying and selling activity for Biohaven Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying Biohaven Pharmaceutical stock?

BHVN stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Polar Capital Holdings Plc, Fisher Asset Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Voloridge Investment Management LLC, Two Sigma Investments LP, and Lord Abbett & CO. LLC.
View insider buying and selling activity for Biohaven Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $105.37.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical has a market capitalization of $6.90 billion and generates $63.63 million in revenue each year. The company earns $-766.80 million in net income (profit) each year or ($13.69) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

Biohaven Pharmaceutical employs 825 workers across the globe.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

Where are Biohaven Pharmaceutical's headquarters?

Biohaven Pharmaceutical is headquartered at 215 CHURCH STREET, NEW HAVEN CT, 06510.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at (203) 404-0410.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.